BioSpace News Archive

Gamida Cell Ltd. today announced that company management will present its corporate highlights at the following upcoming virtual investor conferences: Evercore ISI 4th Annual HealthCONx Conference, November 30, 2021 with a presentation at 1:25 p.m. ET.

enVVeno Medical Corporation, a company setting new standards of care for the treatment of venous disease, announced that Robert Berman, CEO and Marc Glickman, M.D., Senior Vice President and Chief Medical Officer of enVVeno, will participate in the Virtual Investor Roundtable Event on Tuesday, November 16, 2021 at 1:00 PM ET.

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced that Health Canada has approved the companies’ Clinical Trial Application (CTA) for VCTX210,

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) published their summary opinion in support of approval of SIGA’s Marketing Authorisation Application (MAA) for oral tecovirimat.

The new name signifies its expanding focus on collaborative clinical research and broader diagnostic capabilities

Hoth Therapeutics, Inc. today announced that it has signed a Sponsored Research Agreement with North Carolina State University (" NC State ") to support the continued research and development of HT-KIT, a novel therapeutic for the treatment mast cell cancers .

Jaguar Health, Inc. (NASDAQ:JAGX) today announced the appointment of Massimo Mineo, a veteran of Europe’s pharmaceutical industry for 20+ years, as Napo EU’s general manager.

Tenax Therapeutics, Inc. today reported financial results for the third quarter of 2021 and provided a business update.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today reported its 2021 third quarter unaudited financial results.

Deka Biosciences today announced that it has successfully closed a USD 20 Million Series A financing with a syndicate of life science investors led by Leaps by Bayer